Economic Impact of Utilizing a Female External Catheter (FEC) to Reduce the Incidence of Catheter-Associated Urinary Tract Infection (CAUTI): Systematic Review, Analysis, and Model

Author(s)

Kelly T1, Krome H2
1BD Urology and Critical Care, Atlanta, GA, USA, 2Mercer University School of Medicine, Macon, GA, USA

OBJECTIVES: CAUTI is one of the most common, costly, and preventable healthcare-associated infections. CAUTIs result from pathogens entering the urinary tract via indwelling urinary catheters (IUCs). Recently, FECs have been developed as alternatives to IUCs – IUCs can be removed and substituted with FECs in appropriate female patients. A patient will use a single IUC for their stay or course of treatment while FECs must be replaced periodically. The objective of this review and model is to assist organizations in estimating whether FECs offer either/both clinical and economic benefits.

METHODS: A systematic review of research published from 2016 through 2021 (PubMed and Embase databases) assessed the impact of utilization of FECs on organizations’ CAUTI rates. The results were analyzed and applied to a model to estimate the CAUTI cost avoided per day when a FEC is substituted for an IUC.

RESULTS: 270 records were identified. After exclusions, 25 records were reviewed. After excluding records that evaluated the FEC as part of a larger CAUTI prevention bundle, or failed other criteria (denominator issue, case study, or review paper), 8 records were analyzed. 3 studies reported multiple findings (multiple units, multiple hospitals, or multiple evaluation periods). Of the 11 results, 1 reported an increase in CAUTI after implementation of a program to utilize FECs; the remaining 10 reported decreases ranging from an 18.9% to a 100% reduction in the incidence of CAUTI. When applied to the model, the average economic benefit per IUC-day avoided ranged from $5.71 to $30.21 with a mean value of $23.38 per day.

CONCLUSIONS: Utilization of FECs as substitutes for IUCs, in appropriate patients, is likely to reduce an organization’s incidence of CAUTI. Further, the economic benefit may be favorable depending on the baseline incidence of CAUTI, the organization’s cost of CAUTI, and the actual CAUTI reduction achieved.

Conference/Value in Health Info

2022-05, ISPOR 2022, Washington, DC, USA

Value in Health, Volume 25, Issue 6, S1 (June 2022)

Code

MT25

Topic

Clinical Outcomes, Economic Evaluation, Medical Technologies, Study Approaches

Topic Subcategory

Clinical Outcomes Assessment, Cost-comparison, Effectiveness, Utility, Benefit Analysis, Literature Review & Synthesis, Medical Devices

Disease

Urinary/Kidney Disorders

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×